GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Cash-to-Debt

PRTA (Prothena) Cash-to-Debt : 45.18 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Prothena Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prothena's cash to debt ratio for the quarter that ended in Sep. 2024 was 45.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Prothena could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Prothena's Cash-to-Debt or its related term are showing as below:

PRTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.54   Med: 23.59   Max: No Debt
Current: 45.18

During the past 13 years, Prothena's highest Cash to Debt Ratio was No Debt. The lowest was 7.54. And the median was 23.59.

PRTA's Cash-to-Debt is ranked better than
70.48% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs PRTA: 45.18

Prothena Cash-to-Debt Historical Data

The historical data trend for Prothena's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Prothena Cash-to-Debt Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.38 16.56 46.98 109.75 52.29

Prothena Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.50 52.29 43.74 46.56 45.18

Competitive Comparison of Prothena's Cash-to-Debt

For the Biotechnology subindustry, Prothena's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Prothena's Cash-to-Debt falls into.



Prothena Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Prothena's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Prothena's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prothena  (NAS:PRTA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Prothena Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Prothena's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453